Ardelyx, Inc.
Every calculator, already run for ARDX
Open the full toolkit →You have the numbers on ARDX. Get the argument.
A written report on which of these readings actually decide the outcome for Ardelyx, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
11 analysts covering ARDXAnalyst Price Target Disagreement for Ardelyx, Inc.
Wall Street's bull case implies +357% from the current price; the bear case implies +103%. A 254% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Ardelyx, Inc.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
ARDX — frequently asked
Is ARDX a buy right now?
Wall Street's consensus rating on Ardelyx, Inc. is Strong Buy across 11 analysts, with a mean price target of $13.00 (+230% vs. the current $3.94). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ARDX overvalued?
ARDX trades at — trailing earnings, against a DCF fair value of $2 per share. The current price implies 12% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ARDX's next earnings date?
Ardelyx, Inc. is next scheduled to report earnings around Oct 29, 2026. A full ARDX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Ardelyx, Inc.?
Analysts covering Ardelyx, Inc. (ARDX) range from a bear-case target of $8.00 to a bull-case high of $18.00, with a mean consensus target of $13.00 across 10 analysts. The spread of $10.00 (254% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Ardelyx, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Ardelyx, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ARDX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Ardelyx, Inc., in minutes. 3 free reports included with every account — no credit card required.